MYC and neoplasm: Through the integration of in vitro and in vivo methodologies, we elucidate the impact of FDA-approved drugs, HCQ, CQ, and its derivatives, on gene regulation and tumor progression through the stabilization of G4, particularly to c-myc, and highlight their potential therapeutic implications.